JAZZ - Jazz Pharmaceuticals plc Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

JAZZ

JAZZ PHARMACEUTICALS PLC

NASDAQ

$244.54

▼ DOWN 2.61% (-6.56)

KEY STATISTICS

Market Cap$15.36 B

52w High$266.38

52w Low$123.88

Dividend Yield—

Frequency—

P/E9.12

Volume1.19M

Shares Out.62.82M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Renee D. Gala

COMPENSATION 2026

Salary$884,789

Stock Awards$4,855,123

Incentive Plan Pay$0

All Other Comp.$82,441

Total$18,834,836

ABOUT

SECTOR

Healthcare

WENT PUBLIC

June 1, 2007

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

2,890

PRICE TARGET

Target High$322.00

Target Low$229.00

Target Median$299.50

Target Consensus$287.86

UPCOMING EARNINGS

DateNov 4, 2026

DayWednesday

Rev. Est.$1.21B

NOV

WED

PRICE

$244.54 ▼ DOWN 2.61% (−$6.56)

About Jazz Pharmaceuticals plc

https://www.jazzpharma.com ↗

Jazz Pharmaceuticals develops and commercializes neuroscience and oncology products worldwide, including treatments for sleep disorders, narcolepsy, leukemia, and solid tumors.

INDUSTRY

Biotechnology

A PRODUCT JAZZ PHARMACEUTICALS PLC IS KNOWN FOR

Ziihera® (zanidatamab-hrii)

Ziihera, a bispecific antibody approved in 2024 for HER2-positive biliary tract cancer, marks Jazz Pharmaceuticals' strategic shift into oncology with significant future growth potential.

COMPETITORS

COMPETITOR

Revenue by Products

PRODUCT	Q3-2025	Q4-2025	Q1-2026	Q2-2026
Xywav	$431.41M	$465.45M ▲	$408.2M ▼	$471.2M ▲
EpidiolexEpidyolex	$302.61M	$287.12M ▼	$249.8M ▼	$292.1M ▲
Zepzelca	$79.3M	$90.44M ▲	$101M ▲	$105.8M ▲
RylazeEnrylaze	$99.87M	$108.16M ▲	$103.7M ▼	$99.5M ▼
DefitelioDefibrotide	$51.75M	$58.87M ▲	$47.4M ▼	$62M ▲
High Sodium AG Oxybate Product Royalty Revenue	$52.95M	$55.7M ▲	$36.3M ▼	$42.2M ▲
Vyxeos	$37.58M	$34.73M ▼	$26.6M ▼	$31.4M ▲
Xyrem	$35.66M	$37.78M ▲	$31.2M ▼	$30.5M ▼
Ziihera	$8.31M	$8.54M ▲	$13.3M ▲	$15.4M ▲
Other Royalty And Contract Revenues	$8.75M	—	$7.3M ▼	$10M ▲
Other Products	$2.14M	$2.84M ▲	$2.7M ▼	—
Sativex	$4.75M	$1.5M ▼	—	—